Declared Dividend • Aug 10
Second quarter dividend of US$0.70 announced Shareholders will receive a dividend of US$0.70. Ex-date: 17th August 2026 Payment date: 3rd September 2026 Dividend yield will be 0.5%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 10%. Annonce • Aug 07
Chemed Corporation Declares Quarterly Dividend, Payable on September 3, 2026 Chemed Corporation declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on September 3, 2026, to shareholders of record as of August 17, 2026. This is a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026. This represents the 221st consecutive quarterly dividend paid by Chemed in its 55 years as a public company. Recent Insider Transactions • Aug 04
CEO, President & Director recently sold €938k worth of stock On the 3rd of August, Kevin McNamara sold around 2k shares on-market at roughly €469 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Kevin has been a net seller over the last 12 months, reducing personal holdings by €5.5m. Reported Earnings • Jul 29
Second quarter 2026 earnings released: EPS: US$5.14 (vs US$3.60 in 2Q 2025) Second quarter 2026 results: EPS: US$5.14 (up from US$3.60 in 2Q 2025). Revenue: US$673.3m (up 8.8% from 2Q 2025). Net income: US$67.7m (up 29% from 2Q 2025). Profit margin: 10% (up from 8.5% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annonce • Jul 02
Chemed Corporation to Report Q2, 2026 Results on Jul 28, 2026 Chemed Corporation announced that they will report Q2, 2026 results After-Market on Jul 28, 2026 Recent Insider Transactions • Jun 11
Independent Director recently sold €521k worth of stock On the 9th of June, Andrea Lindell sold around 1k shares on-market at roughly €387 per share. This transaction amounted to 23% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €716k. Insiders have been net sellers, collectively disposing of €8.9m more than they bought in the last 12 months. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Eileen McCarthy was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Declared Dividend • May 25
First quarter dividend of US$0.60 announced Shareholders will receive a dividend of US$0.60. Ex-date: 28th May 2026 Payment date: 16th June 2026 Dividend yield will be 0.6%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 13%. Cash payout ratio: 8%. Annonce • May 20
Chemed Corporation Declares Quarterly Cash Dividend, Payable on June 16, 2026 Chemed Corporation at the annual stockholders’ meeting held on May 18, 2026 declared a quarterly cash dividend of 60 cents per share on the Company’s capital stock, payable on June 16, 2026, to stockholders of record as of May 28, 2026. Annonce • Apr 07
Chemed Corporation, Annual General Meeting, May 18, 2026 Chemed Corporation, Annual General Meeting, May 18, 2026. Location: queen city club, 331 east fourth street, cincinnati, ohio, United States Annonce • Apr 02
Chemed Corporation to Report Q1, 2026 Results on Apr 23, 2026 Chemed Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2026 Annonce • Feb 26
Chemed Corporation Provides Consolidated Earnings Guidance for the Year 2026 Chemed Corporation provided consolidated earnings guidance for the year 2026. For the full-year 2026 earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $23.25 to $24.25. Annonce • Feb 14
Chemed Corporation Declares Quarterly Cash Dividend, Payable on March 13, 2026 Chemed Corporation announced the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, payable on March 13, 2026, to shareholders of record as of February 23, 2026. This is equal to the dividend paid in December 2025. This represents the 219th consecutive quarterly dividend paid by Chemed in its 54 years as a public company. Annonce • Jan 03
Chemed Corporation to Report Q4, 2025 Results on Feb 25, 2026 Chemed Corporation announced that they will report Q4, 2025 results After-Market on Feb 25, 2026 Annonce • Nov 07
Chemed Corporation Declares Quarterly Cash Dividend, Payable on December 5, 2025 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, payable on December 5, 2025, to shareholders of record as of November 17, 2025. Annonce • Oct 29
Chemed Corporation Reiterates Earnings Guidance for the Year 2025 Chemed Corporation reiterated earnings guidance for the year 2025. For the year, management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items. Annonce • Oct 01
Chemed Corporation to Report Q3, 2025 Results on Oct 28, 2025 Chemed Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025 Annonce • Aug 02
Chemed Corporation Declares Quarterly Cash Dividend on Capital Stock, Payable on August 29, 2025 The Board of Directors of Chemed Corporation has declared a quarterly cash dividend of 60 cents per share on the Company’s capital stock, payable on August 29, 2025, to shareholders of record as of August 11, 2025. This is a 10 cents, or 20.0%, increase over the 50 cents dividend paid in June 2025. Annonce • Jun 28
Chemed Corporation to Report Q2, 2025 Results on Jul 29, 2025 Chemed Corporation announced that they will report Q2, 2025 results After-Market on Jul 29, 2025 Annonce • May 20
Chemed Corporation Declares Quarterly Dividend, Payable on June 17, 2025 Chemed Corporation declared a quarterly cash dividend of 50 cents per share on the Company’s capital stock, payable on June 17, 2025, to stockholders of record as of May 29, 2025. This represents the 216th consecutive quarterly dividend paid to stockholders in Chemed’s 54 years as a public company. Annonce • Apr 03
Chemed Corporation, Annual General Meeting, May 19, 2025 Chemed Corporation, Annual General Meeting, May 19, 2025. Annonce • Apr 01
Chemed Corporation to Report Q1, 2025 Results on Apr 23, 2025 Chemed Corporation announced that they will report Q1, 2025 results After-Market on Apr 23, 2025 Annonce • Feb 15
Chemed Corporation Declares Quarterly Dividend, Payable on March 14, 2025 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on March 14, 2025, to shareholders of record as of February 24, 2025. Annonce • Feb 12
Chemed Corporation to Report Q4, 2024 Results on Feb 26, 2025 Chemed Corporation announced that they will report Q4, 2024 results After-Market on Feb 26, 2025 Annonce • Nov 08
Chemed Corporation Declares Quarterly Dividend, Payable on December 6, 2024 Chemed Corporation declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on December 6, 2024, to shareholders of record as of November 18, 2024. This is equal to the dividend paid in August 2024. This represents the 214 consecutive quarterly dividend paid by Chemed in its 53 years as a public company. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: US$5.04 (vs US$4.97 in 3Q 2023) Third quarter 2024 results: EPS: US$5.04 (up from US$4.97 in 3Q 2023). Revenue: US$606.2m (up 7.4% from 3Q 2023). Net income: US$75.8m (up 1.1% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Oct 30
Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024 Chemed Corporation revised consolidated earnings guidance for the full year 2024. For the full-year consolidated 2024 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $23.00 to $23.15. This range represents a 13.3% to 14.0% increase from it’s 2023 reported adjusted earnings per diluted share of $20.30. Recent Insider Transactions • Sep 29
CEO, President & Director recently sold €1.1m worth of stock On the 26th of September, Kevin McNamara sold around 2k shares on-market at roughly €536 per share. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €2.5m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €7.0m. Annonce • Sep 14
Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024 Chemed Corporation announced that they will report Q3, 2024 results After-Market on Oct 29, 2024 Recent Insider Transactions • Sep 11
Executive Vice President recently sold €883k worth of stock On the 9th of September, Nicholas Westfall sold around 2k shares on-market at roughly €516 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €2.5m. Insiders have been net sellers, collectively disposing of €22m more than they bought in the last 12 months. Annonce • Aug 03
Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on August 30, 2024, to shareholders of record as of August 12, 2024. This is a 10-cent, or 25.0%, increase over the 40-cent dividend paid in June 2024. Recent Insider Transactions • Aug 02
Executive Vice President recently sold €1.0m worth of stock On the 30th of July, Nicholas Westfall sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €2.1m. Insiders have been net sellers, collectively disposing of €20m more than they bought in the last 12 months. Reported Earnings • Jul 25
Second quarter 2024 earnings released: EPS: US$4.70 (vs US$3.55 in 2Q 2023) Second quarter 2024 results: EPS: US$4.70 (up from US$3.55 in 2Q 2023). Revenue: US$595.9m (up 7.6% from 2Q 2023). Net income: US$70.9m (up 33% from 2Q 2023). Profit margin: 12% (up from 9.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Annonce • Jul 02
Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024 Chemed Corporation announced that they will report Q2, 2024 results After-Market on Jul 24, 2024 Recent Insider Transactions • Jun 10
CEO, President & Director recently sold €750k worth of stock On the 6th of June, Kevin McNamara sold around 2k shares on-market at roughly €500 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.1m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €7.1m. Declared Dividend • May 27
First quarter dividend of US$0.40 announced Shareholders will receive a dividend of US$0.40. Ex-date: 30th May 2024 Payment date: 18th June 2024 Dividend yield will be 0.3%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 8%. Annonce • May 22
Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024 Chemed Corporation’s Board of Directors declared a quarterly cash dividend of 40 cents per share on the Company’s capital stock, payable on June 18, 2024, to stockholders of record as of May 30, 2024. Recent Insider Transactions • May 19
CEO, President & Director recently sold €2.1m worth of stock On the 16th of May, Kevin McNamara sold around 4k shares on-market at roughly €522 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Kevin has been a net seller over the last 12 months, reducing personal holdings by €6.3m. Annonce • Apr 26
Chemed Corporation Reiterates Earnings Guidance for Full Year 2024 Chemed Corporation reiterates earnings guidance for full year 2024. For the full year, company reiterates earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, guidance range of $23.30 to $23.70. Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: US$4.30 (vs US$3.62 in 1Q 2023) First quarter 2024 results: EPS: US$4.30 (up from US$3.62 in 1Q 2023). Revenue: US$589.2m (up 5.2% from 1Q 2023). Net income: US$65.0m (up 20% from 1Q 2023). Profit margin: 11% (up from 9.7% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Annonce • Apr 09
Chemed Corporation, Annual General Meeting, May 20, 2024 Chemed Corporation, Annual General Meeting, May 20, 2024, at 11:00 US Eastern Standard Time. Location: The Queen City Club 331 East Fourth Street Cincinnati United States New Risk • Apr 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 14% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Minor Risk Significant insider selling over the past 3 months (€1.4m sold). Annonce • Apr 02
Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024 Chemed Corporation announced that they will report Q1, 2024 results After-Market on Apr 24, 2024 Recent Insider Transactions • Apr 02
Executive Vice President recently sold €1.2m worth of stock On the 28th of March, Spencer Lee sold around 2k shares on-market at roughly €594 per share. This transaction amounted to 7.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €18m more than they bought in the last 12 months. Buy Or Sell Opportunity • Mar 05
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 10% to €585. The fair value is estimated to be €478, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 7.3%. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 30% in the next 2 years. Reported Earnings • Feb 28
Full year 2023 earnings released: EPS: US$18.11 (vs US$16.72 in FY 2022) Full year 2023 results: EPS: US$18.11 (up from US$16.72 in FY 2022). Revenue: US$2.26b (up 6.1% from FY 2022). Net income: US$272.5m (up 9.2% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Annonce • Feb 17
Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on March 15, 2024, to shareholders of record as of February 26, 2024. This is equal to the dividend paid in December 2023. Annonce • Feb 15
Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024 Chemed Corporation announced that they will report Q4, 2023 results After-Market on Feb 27, 2024 Annonce • Dec 19
Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024 On December 18, 2023, Chemed Corporation’s board of directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of David P. Williams from that role. Mr. Witzeman is currently the company’s Vice President and Controller and serves as the company’s principal accounting officer. He joined the company in 2005 following employment as Senior Manager of Assurance at Deloitte & Touche LLP. He is a licensed CPA and a BBA in Accounting from the University of Cincinnati and an MBA from The Ohio State University. Recent Insider Transactions • Dec 15
CEO, President & Director recently sold €800k worth of stock On the 11th of December, Kevin McNamara sold around 2k shares on-market at roughly €533 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.3m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €8.7m. Recent Insider Transactions • Nov 28
Executive Vice President recently sold €530k worth of stock On the 27th of November, Spencer Lee sold around 1k shares on-market at roughly €530 per share. This transaction amounted to 4.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.3m. Insiders have been net sellers, collectively disposing of €21m more than they bought in the last 12 months. Annonce • Nov 05
Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023 Chemed Corporation announced that after more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed’s Chief Financial Officer as of December 31, 2023, but Mr. Williams will continue to work with Chemed for the transition period and beyond in providing his guidance and the benefit of his expertise to the executive team and the Board of Directors. Throughout his career, David helped lead Chemed and its subsidiaries through unprecedented economic growth. David joined Chemed in 1990 as Vice President of Finance for The Omnia Group, a former subsidiary engaged in the manufacture and distribution of medical and dental products, and has served in a number of other roles with Chemed and its subsidiaries, including Roto-Rooter Management Company, since that time. In March 2004, the Chemed Board of Directors elected Mr. Williams a Vice President and the Chief Financial Officer of Chemed. In August 2007, he was named an Executive Vice President of Chemed, while retaining his title of CFO. Annonce • Nov 04
Chemed Corporation Declares Quarterly Cash Dividend, Payable on December 4, 2023 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on December 4, 2023, to shareholders of record as of November 13, 2023. This is equal to the dividend paid in September 2023. Recent Insider Transactions • Nov 02
CEO, President & Director recently sold €1.6m worth of stock On the 31st of October, Kevin McNamara sold around 3k shares on-market at roughly €531 per share. This transaction amounted to 2.5% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €1.9m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €9.8m. Annonce • Oct 28
Chemed Corporation Provides Earnings Guidance for the Full-Year 2023 Chemed Corporation provided earnings guidance for the full-year 2023. For the year, the company's earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, is estimated to be in the range of $19.82 to $20.02. Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: US$4.97 (vs US$3.82 in 3Q 2022) Third quarter 2023 results: EPS: US$4.97 (up from US$3.82 in 3Q 2022). Revenue: US$564.5m (up 7.2% from 3Q 2022). Net income: US$75.0m (up 32% from 3Q 2022). Profit margin: 13% (up from 11% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Annonce • Oct 12
Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023 Chemed Corporation announced that they will report Q3, 2023 results After-Market on Oct 25, 2023 Recent Insider Transactions • Aug 08
CEO, President & Director recently sold €1.9m worth of stock On the 3rd of August, Kevin McNamara sold around 4k shares on-market at roughly €472 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Kevin has been a net seller over the last 12 months, reducing personal holdings by €11m. Reported Earnings • Jul 27
Second quarter 2023 earnings released: EPS: US$3.55 (vs US$4.45 in 2Q 2022) Second quarter 2023 results: EPS: US$3.55 (down from US$4.45 in 2Q 2022). Revenue: US$553.8m (up 4.2% from 2Q 2022). Net income: US$53.4m (down 20% from 2Q 2022). Profit margin: 9.6% (down from 13% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Annonce • Jul 13
Chemed Corporation to Report Q2, 2023 Results on Jul 26, 2023 Chemed Corporation announced that they will report Q2, 2023 results on Jul 26, 2023 Recent Insider Transactions • May 31
Independent Director recently sold €149k worth of stock On the 26th of May, Patrick Grace sold around 294 shares on-market at roughly €508 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €2.0m. Insiders have been net sellers, collectively disposing of €18m more than they bought in the last 12 months. Recent Insider Transactions • May 09
CEO, President & Director recently sold €2.0m worth of stock On the 5th of May, Kevin McNamara sold around 4k shares on-market at roughly €499 per share. This transaction amounted to 3.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Kevin has been a net seller over the last 12 months, reducing personal holdings by €9.7m. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: US$3.62 (vs US$4.28 in 1Q 2022) First quarter 2023 results: EPS: US$3.62 (down from US$4.28 in 1Q 2022). Revenue: US$560.2m (up 5.6% from 1Q 2022). Net income: US$54.1m (down 16% from 1Q 2022). Profit margin: 9.7% (down from 12% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Recent Insider Transactions • Mar 22
Executive VP & CFO recently sold €2.0m worth of stock On the 20th of March, David Williams sold around 4k shares on-market at roughly €488 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by €7.2m. Recent Insider Transactions • Mar 12
CEO, President & Director recently sold €959k worth of stock On the 9th of March, Kevin McNamara sold around 2k shares on-market at roughly €480 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Kevin has been a net seller over the last 12 months, reducing personal holdings by €7.7m. Reported Earnings • Feb 24
Full year 2022 earnings released: EPS: US$16.72 (vs US$17.14 in FY 2021) Full year 2022 results: EPS: US$16.72 (down from US$17.14 in FY 2021). Revenue: US$2.13b (flat on FY 2021). Net income: US$249.6m (down 7.0% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 8% per year. Annonce • Feb 18
Chemed Corporation Declares Quarterly Cash Dividend Payable on March 17, 2023 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on March 17, 2023, to shareholders of record as of February 27, 2023. This is equal to the dividend paid in December 2022. This represents the 207th consecutive quarterly dividend paid by Chemed in its 50 years as a public company. Annonce • Feb 10
Chemed Corporation to Report Q4, 2022 Results on Feb 23, 2023 Chemed Corporation announced that they will report Q4, 2022 results After-Market on Feb 23, 2023 Recent Insider Transactions • Nov 23
CEO, President & Director recently sold €987k worth of stock On the 21st of November, Kevin McNamara sold around 2k shares on-market at roughly €494 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €3.9m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €7.1m. Recent Insider Transactions • Nov 16
Executive VP & CFO recently sold €3.9m worth of stock On the 10th of November, David Williams sold around 8k shares on-market at roughly €489 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by €5.2m. Recent Insider Transactions • Nov 05
CEO, President & Director recently sold €990k worth of stock On the 3rd of November, Kevin McNamara sold around 2k shares on-market at roughly €495 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €1.4m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €7.4m. Annonce • Nov 05
Chemed Corporation Declares Quarterly Cash Dividend on the Capital Stock, Payable on December 5, 2022 Chemed Corporation announced that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on December 5, 2022, to shareholders of record as of November 14, 2022. This is equal to the dividend paid in September 2022. This represents the 206th consecutive quarterly dividend paid by Chemed in its 51 years as a public company. Reported Earnings • Nov 02
Third quarter 2022 earnings released: EPS: US$3.82 (vs US$4.62 in 3Q 2021) Third quarter 2022 results: EPS: US$3.82 (down from US$4.62 in 3Q 2021). Revenue: US$526.5m (down 2.3% from 3Q 2021). Net income: US$56.9m (down 21% from 3Q 2021). Profit margin: 11% (down from 13% in 3Q 2021). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year and the company’s share price has also increased by 8% per year. Annonce • Nov 01
Chemed Corporation Provides Earnings Guidance for the Year 2022 Chemed Corporation announced that for full-year 2022 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, retention program for licensed healthcare employees, and other discrete items, is estimated to be in the range of $19.60 to $19.70. Annonce • Oct 18
Chemed Corporation to Report Q3, 2022 Results on Oct 31, 2022 Chemed Corporation announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Oct 31, 2022 Recent Insider Transactions • Sep 15
CEO, President & Director recently sold €948k worth of stock On the 13th of September, Kevin McNamara sold around 2k shares on-market at roughly €474 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €1.4m. Kevin has been a net seller over the last 12 months, reducing personal holdings by €6.5m. Recent Insider Transactions • Aug 23
CEO, President & Director recently sold €1.4m worth of stock On the 18th of August, Kevin McNamara sold around 3k shares on-market at roughly €475 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by €5.5m. Annonce • Jul 29
Chemed Corporation Provides Earnings Guidance for the Year 2022 Chemed Corporation provided earnings guidance for the year 2022. Based upon the above, full-year 2022 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $19.30 to $19.50. Reported Earnings • Jul 28
Second quarter 2022 earnings released: EPS: US$4.45 (vs US$3.57 in 2Q 2021) Second quarter 2022 results: EPS: US$4.45 (up from US$3.57 in 2Q 2021). Revenue: US$531.3m (flat on 2Q 2021). Net income: US$66.5m (up 18% from 2Q 2021). Profit margin: 13% (up from 11% in 2Q 2021). Over the next year, revenue is forecast to grow 3.8%, compared to a 4.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year. Annonce • Jul 07
Chemed Corporation to Report Q2, 2022 Results on Jul 27, 2022 Chemed Corporation announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Jul 27, 2022 Recent Insider Transactions • Jun 14
Independent Director recently sold €116k worth of stock On the 10th of June, Patrick Grace sold around 262 shares on-market at roughly €442 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.4m. Insiders have been net sellers, collectively disposing of €9.0m more than they bought in the last 12 months. Annonce • May 17
Chemed Corporation Declares Quarterly Cash Dividend, Payable on June 15, 2022 Chemed Corporation Board of Directors declared a quarterly cash dividend of 36 cents per share on the Company’s capital stock, payable on June 15, 2022, to stockholders of record as of May 26, 2022. Recent Insider Transactions • May 05
CEO, President & Director recently sold €1.4m worth of stock On the 2nd of May, Kevin McNamara sold around 3k shares on-market at roughly €463 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by €5.5m. Reported Earnings • Apr 28
First quarter 2022 earnings released: EPS: US$4.28 (vs US$4.09 in 1Q 2021) First quarter 2022 results: EPS: US$4.28. Revenue: US$530.5m (flat on 1Q 2021). Net income: US$64.2m (down 1.9% from 1Q 2021). Profit margin: 12% (in line with 1Q 2021). Over the next year, revenue is forecast to grow 3.0%, compared to a 5.7% growth forecast for the industry in Germany. Recent Insider Transactions • Apr 15
Independent Director recently sold €194k worth of stock On the 7th of April, Donald Saunders sold around 405 shares on-market at roughly €478 per share. In the last 3 months, there was an even bigger sale from another insider worth €473k. Insiders have been net sellers, collectively disposing of €10m more than they bought in the last 12 months. Annonce • Apr 09
Chemed Corporation, Annual General Meeting, May 16, 2022 Chemed Corporation, Annual General Meeting, May 16, 2022, at 11:00 US Eastern Standard Time. Location: Queen City Club, 331 East Fourth Street Cincinnati Ohio United States Agenda: To elect directors; to approve and adopt the Company's 2022 Stock Incentive Plan; to ratify the selection of independent accountants by the Audit Committee of the Board of Directors; to hold an advisory vote to approve executive compensation; and to transact any other business properly brought before the meeting. Annonce • Apr 08
Chemed Corporation to Report Q1, 2022 Results on Apr 26, 2022 Chemed Corporation announced that they will report Q1, 2022 results After-Market on Apr 26, 2022 Recent Insider Transactions • Mar 09
Executive Vice President recently sold €473k worth of stock On the 7th of March, Spencer Lee sold around 1k shares on-market at roughly €449 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €9.4m more than they bought in the last 12 months. Reported Earnings • Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$17.14 (down from US$20.02 in FY 2020). Revenue: US$2.14b (up 2.9% from FY 2020). Net income: US$268.6m (down 16% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.3%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. 
